| Ident. | Authors (with country if any) | Title |
|---|
| 000007 |
Shahnaj Begum [Finlande] | Impact of Climate Change on Elderly People in the Arctic, with Special Focus on the European High North: A Human Rights Perspective |
| 000035 |
A Yu Meigal [Russie] ; S M Rissanen [Finlande] ; M P Tarvainen [Finlande] ; S D Georgiadis [Finlande] ; P A Karjalainen [Finlande] ; O. Airaksinen [Finlande] ; M. Kankaanp [Finlande] | Linear and nonlinear tremor acceleration characteristics in patients with Parkinson's disease |
| 000128 |
M. S. Lee [Corée du Sud] ; C. H. Lyoo [Corée du Sud] ; Y. H. Ryu [Corée du Sud] ; H. S. Lim [Corée du Sud] ; C. M. Nam [Corée du Sud] ; H. S. Kim [Corée du Sud] ; J. O. Rinne [Finlande] | The effect of age on motor deficits and cerebral glucose metabolism of Parkinson’s disease |
| 000164 |
Claudia Trenkwalder [Allemagne] ; Bryan Kies [Afrique du Sud] ; Monika Rudzinska [Pologne] ; Jennifer Fine [Afrique du Sud] ; Janos Nikl [Hongrie] ; Krystyna Honczarenko [Pologne] ; Peter Dioszeghy [Hongrie] ; Dennis Hill [États-Unis] ; Tim Anderson [Nouvelle-Zélande] ; Vilho Myllyla [Finlande] ; Jan Kassubek [Allemagne] ; Malcolm Steiger [Royaume-Uni] ; Marco Zucconi [Italie] ; Eduardo Tolosa [Espagne] ; Werner Poewe [Autriche] ; Erwin Surmann [Allemagne] ; John Whitesides [États-Unis] ; Babak Boroojerdi [Allemagne] ; Kallol Ray Chaudhuri [Royaume-Uni] ; the RECOVER Study Group | Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER) |
| 000174 |
M. Matinolli [Finlande] ; J. T. Korpelainen [Finlande] ; K. A. Sotaniemi [Finlande] ; V. V. Myllyl [Finlande] ; R. Korpelainen [Finlande] | Recurrent falls and mortality in Parkinson’s disease: a prospective two‐year follow‐up study |
| 000272 |
P. Stathis [Grèce] ; S. Konitsiotis [Grèce] ; G. Tagaris [Grèce] ; D. Peterson [Finlande] | Levetiracetam for the management of levodopa‐induced dyskinesias in Parkinson's disease |
| 000722 |
M. Soilu-H Nninen ; E. Broberg ; M. Röytt ; P. Mattila ; J. Rinne [Finlande] ; V. Hukkanen [Finlande] | Expression of LIF and LIF receptor beta in Alzheimer’s and Parkinson’s diseases |
| 000748 |
Elina Parviainen [Finlande] | Dimension Reduction for Regression with Bottleneck Neural Networks |
| 000A02 |
Arja Mainio [Finlande] ; Kaisa Karvonen [Finlande] ; Helin Hakko [Finlande] ; Terttu S Rkioja [Finlande] ; Pirkko R S Nen [Finlande] | Parkinson's disease and suicide: a profile of suicide victims with Parkinson's disease in a population‐based study during the years 1988–2002 in Northern Finland |
| 000A10 |
Maarit Matinolli [Finlande] ; Juha T. Korpelainen [Finlande] ; Raija Korpelainen [Finlande] ; Kyösti A. Sotaniemi [Finlande] ; Vilho V. Myllyl [Finlande] | Orthostatic hypotension, balance and falls in Parkinson's disease |
| 000A31 |
M. Matinolli [Finlande] ; J. T. Korpelainen [Finlande] ; R. Korpelainen [Finlande] ; K. A. Sotaniemi [Finlande] ; V. Matinolli [Finlande] ; V. V. Myllyl [Finlande] | Mobility and balance in Parkinson’s disease: a population‐based study |
| 000B04 |
H. Nissinen [Finlande] ; M. Kuoppam Ki [Finlande] ; M. Leinonen [Suède] ; A. H. Schapira [Royaume-Uni] | Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis |
| 000B79 |
Anna Brück [Finlande] ; Sargo Aalto [Finlande] ; Elina Rauhala [Finlande] ; Jörgen Bergman [Finlande] ; Reijo Marttila [Finlande] ; Juha O. Rinne [Finlande] | A follow‐up study on 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen |
| 000C00 |
C. H. Lyoo [Finlande] ; Y. Jeong [Finlande] ; Y. H. Ryu [Finlande] ; S. Y. Lee [Finlande] ; T. J. Song [Finlande] ; J. H. Lee [Finlande] ; J. O. Rinne [Finlande] ; M. S. Lee [Finlande] | Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy |
| 000D88 |
Aki S. Havulinna [Finlande] ; Pentti J. Tienari [Finlande] ; Reijo J. Marttila [Finlande] ; Kirsti K. Martikainen [Finlande] ; Johan G. Eriksson [Finlande] ; Olli Taskinen [Finlande] ; Elena Moltchanova [Finlande] ; Marjatta Karvonen [Finlande] | Geographical variation of medicated parkinsonism in Finland during 1995 to 2000 |
| 000F56 |
V. Pursiainen [Finlande] ; T. J. Korpelainen [Finlande] ; H. T. Haapaniemi [Finlande] ; A. K. Sotaniemi [Finlande] ; V. V. Myllyl [Finlande] | Selegiline and blood pressure in patients with Parkinson's disease |
| 000F86 |
Maarit Matinolli [Finlande] ; Juha T. Korpelainen [Finlande] ; Raija Korpelainen [Finlande] ; Kyösti A. Sotaniemi [Finlande] ; Minna Virranniemi [Finlande] ; Vilho V. Myllyl [Finlande] | Postural sway and falls in Parkinson's disease: A regression approach |
| 001021 |
Tua Annanmaki [Finlande] ; Antti Muuronen [Finlande] ; Kari Murros [Finlande] | Low plasma uric acid level in Parkinson's disease |
| 001074 |
Chul Hyoung Lyoo [Corée du Sud] ; Sargo Aalto [Finlande] ; Juha O. Rinne [Finlande] ; Ki Ook Lee [Corée du Sud] ; Seung Hun Oh [Corée du Sud] ; Jin Woo Chang [Corée du Sud] ; Myung Sik Lee [Corée du Sud] | Different cerebral cortical areas influence the effect of subthalamic nucleus stimulation on parkinsonian motor deficits and freezing of gait |
| 001095 |
Gang Hu [Finlande] ; Siamak Bidel [Finlande] ; Pekka Jousilahti [Finlande] ; Riitta Antikainen [Finlande] ; Jaakko Tuomilehto [Finlande] | Coffee and tea consumption and the risk of Parkinson's disease |
| 001107 |
V. Pursiainen [Finlande] ; J. T. Korpelainen ; T. H. Haapaniemi ; K. A. Sotaniemi ; V. V. Myllyl | Blood pressure and heart rate in parkinsonian patients with and without wearing‐off |
| 001241 |
Kirsti K. Martikainen [Finlande] ; Tiina H. Luukkaala [Finlande] ; Reijo J. Marttila [Finlande] | Parkinson's disease and working capacity |
| 001275 |
Antti J. V N Nen [Finlande] ; Pekka Rauhala [Finlande] ; Raimo K. Tuominen [Finlande] ; P Ivi Liesi [Finlande, États-Unis] | KDI tripeptide of γ1 laminin protects rat dopaminergic neurons from 6‐OHDA induced toxicity |
| 001388 |
Laura Parkkinen [Finlande] ; Tuula Pirttil [Finlande] ; Markku Tervahauta [Finlande] ; Irina Alafuzoff [Finlande] | Widespread and abundant α‐synuclein pathology in a neurologically unimpaired subject |
| 001462 |
Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Mikko Kuoppamaki [Royaume-Uni, États-Unis] ; Warren Olanow [Finlande] ; Peter Jenner [Royaume-Uni] | Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates |
| 001482 |
J. Eerola [Finlande] ; P J Tienari [Finlande] ; S. Kaakkola [Finlande] ; P. Nikkinen ; J. Launes [Finlande] | How useful is [123I]β-CIT SPECT in clinical practice? |
| 001758 |
N. Kemppainen [Finlande] ; M. Laine [Finlande] ; M. P. Laakso [Finlande] ; V. Kaasinen [Finlande] ; K. N Gren [Finlande] ; T. Vahlberg [Finlande] ; T. Kurki [Finlande] ; J. O. Rinne [Finlande] | Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease |
| 001898 |
Werner Poewe [Autriche] ; G. Deuschl ; A. Gordin [Finlande] ; E. Kultalahti [Finlande] ; M. Leinonen [Finlande] | Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study) |
| 001990 |
Juha O. Rinne [Finlande] ; Elina Nurmi [Finlande] ; Hanna M. Ruottinen [Finlande] ; Jörgen Bergman [Finlande] ; Olli Eskola [Finlande] ; Olof Solin [Finlande] | [18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease |
| 001991 |
Tarja H. Haapaniemi [Finlande] ; Aapo Ahonen [Finlande] ; Pentti Torniainen [Finlande] ; Kyösti A. Sotaniemi [Finlande] ; Vilho V. Myllyl [Finlande] | [123I]β‐CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients |
| 001A00 |
V. V. Myllyl ; E. Kultalahti [Finlande] ; H. Haapaniemi [Finlande] ; M. Leinonen [Finlande] | Twelve‐month safety of entacapone in patients with Parkinson’s disease |
| 001A31 |
Anna Brück [Finlande] ; Raija Portin [Finlande] ; Arja Lindell [Finlande] ; Arto Laihinen [Finlande] ; Jörgen Bergman [Finlande] ; Merja Haaparanta [Finlande] ; Olof Solin [Finlande] ; Juha O. Rinne [Finlande] | Positron emission tomography shows that impaired frontal lobe functioning in Parkinson’s disease is related to dopaminergic hypofunction in the caudate nucleus |
| 001B03 |
Björn Holmberg [Suède] ; Mika Kallio [Finlande] ; Bo Johnels [Suède] ; Mikael Elam [Suède] | Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of Parkinsonian syndromes |
| 001C34 |
J. Lyytinen [Finlande] ; S. Kaakkola [Finlande] ; A. Gordin [Finlande] ; E.-R Kultalahti [Finlande] ; H. Ter V Inen [Finlande] | Entacapone and selegiline with l-dopa in patients with Parkinson's disease: an interaction study |
| 001C61 |
Oleg V. Anichtchik [Finlande] ; Juha O. Rinne [Finlande] ; Hannu Kalimo [Finlande] ; Pertti Panula [Finlande] | An Altered Histaminergic Innervation of the Substantia Nigra in Parkinson's Disease |
| 001D39 |
H. Przuntek ; B. Conrad [Allemagne] ; J. Dichgans ; P. H. Kraus ; P. Krauseneck ; G. Pergande ; U. Rinne [Finlande] ; K. Schimrigk ; J. Schnitker ; H. P. Vogel [Allemagne] | SELEDO: a 5‐y‐ear long‐term trial on the effect of selegiline in early parkinsonian patients treated with levodopa |
| 001D92 |
Anne-Maria Kuopio [Finlande] ; Reijo J. Marttila [Finlande] ; Hans Helenius [Finlande] ; Urpo K. Rinne [Finlande] | Environmental risk factors in Parkinson's disease |
| 001F63 |
Shuang Yong Ma [Finlande] ; Matias Röytt [Finlande] ; Juha O. Rinne [Finlande] ; Yrjö Collan [Finlande] ; Urpo K. Rinne [Finlande] | Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts |
| 001F85 |
Satu-Mari Kokko [Finlande] ; Jaana Paltamaa [Finlande] ; Erja Ahola [Finlande] ; Esko M Lki [Finlande] | The assessment of functional ability in patients with Parkinson's disease: The PLM‐test and three clinical tests |
| 001F92 |
V. V. Myllyl [Finlande] ; K. A. Sotaniemi [Finlande] ; P. Hakulinen [Finlande] ; O. M Ki-Lkola [Finlande] ; E. H. Heinonen [Finlande] | Selegiline as the primary treatment of Parkinson's disease — a long‐term double‐blind study |
| 002033 |
V. V. Myllyl [Finlande] ; M. Jackson [Royaume-Uni] ; J. P. Larsen [Norvège] ; H. Baas [Allemagne] | Efficacy and safety of tolcapone in levodopa‐treated Parkinson's disease patients with “wearing‐off” phenomenon: a multicentre, double‐blind, randomized, placebo‐controlled trial |
| 002115 |
Shuang Yong Ma [Finlande] ; Juha O. Rinne [Finlande] ; Yrjö Collan [Finlande] ; Matias Röytt [Finlande] ; Urpo K. Rinne [Finlande] | A quantitative morphometrical study of neuron degeneration in the substantia nigra in Parkinson's disease |
| 002162 |
T. Autti [Finlande] ; R. Raininko ; L. Vanhanen [Finlande] ; P. Santavuori [Finlande] | MRI of neuronal ceroid lipofuscinosis |
| 002224 |
Juha O. Rinne [Finlande] ; Jyrki T. Kuikka [Finlande] ; Kim A. Bergström [Finlande] ; Urpo K. Rinne [Finlande] | Striatal dopamine transporter in different disability stages of Parkinson's disease studied with [123I]β-CIT SPECT |
| 002247 |
Juha O. Rinne [Finlande] ; Arto Laihinen [Finlande] ; Hanna Ruottinen [Finlande] ; Ulla Ruotsalainen [Finlande] ; Kjell N Gren [Finlande] ; Pertti Lehikoinen [Finlande] ; Vesa Oikonen [Finlande] ; U. K. Rinne [Finlande] | Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride |
| 002267 |
P. Laakso [Finlande] ; H. Soininen [Finlande] ; K. Partanen [Finlande] ; -L. Helkala [Finlande] ; P. Hartikainen [Finlande] ; P. Vainio [Finlande] ; M. Hallikainen [Finlande] ; T. H Nninen [Finlande] ; J. Riekkinen Sr [Finlande] | Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: Correlation with memory functions |
| 002300 |
Juha O. Rinne [Finlande] ; Arto Laihinen [Finlande] ; Kjell N Gren [Finlande] ; Hanna Ruottinen [Finlande] ; Ulla Ruotsawnen [Finlande] ; Urpo K. Rinne [Finlande] | PET examination of the monoamine transporter with [11c]β‐CIT and [11c]β‐CFT in early parkinson's disease |
| 002418 |
Juha Nousiainen [Finlande] ; Sakari Oja [Finlande] ; Jaakko Malmivuo | Normal vector magnetocardiogram |
| 002432 |
T. Ker Nen [Finlande] ; A. Gordin [Finlande] ; M. Karlsson [Finlande] ; K. Korpela [Finlande] ; J. Pentik Inen [Finlande] ; H. Rita [Finlande] ; E. Schultz [Finlande] ; L. Sepp L [Finlande] ; T. Wikberg [Finlande] | Inhibition of soluble catechol- O -methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone |
| 002478 |
M. M Kij Rvi [Finlande] ; J. Nenonen ; L. Toivonen [Finlande] ; J. Montonen ; T. Katila ; P. Siltanen [Finlande] | Magnetocardiography: Supraventricular arrhythmias and preexcitation syndromes |
| 002528 |
Rinne [Finlande] | Nigral degeneration in parkinson's disease |
| 002549 |
H. Heinonen [Finlande] ; M. Savij Rvi [Finlande] ; M. Kotila [Finlande] ; A. Hajba [Finlande] ; M. Scheinin [Finlande] | Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease |
| 002579 |
Markku M Kij Rvi [Finlande] ; Jukka Nenonen [Finlande] ; Matti Leiniö [Finlande] ; Juha Montonen [Finlande] ; Lauri Toivonen [Finlande] ; Markku S. Nieminen [Finlande] ; Toivo Katila [Finlande] ; Pentti Siltanen [Finlande] | Localization of accessory pathways in Wolff-Parkinson-White syndrome by high-resolution magnetocardiographic mapping |
| 002626 |
P. Hartikainen [Finlande] ; J. Reinikainen [Finlande] ; H. Soininen [Finlande] ; J. Sirviö [Finlande] ; R. Soikkeli [Finlande] ; J. Riekkinen [Finlande] | Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls |
| 002639 |
H. Soininen [Finlande] ; -L. Helkala [Finlande] ; V. Laulumaa [Finlande] ; R. Soikkeli [Finlande] ; P. Hartikainen [Finlande] ; J. Riekkinen [Finlande] | Cognitive profile of Alzheimer patients with extrapyramidal signs: A longitudinal study |
| 002686 |
R. J. Marttila [Finlande] ; U. K. Rinne [Finlande] ; R. J. Marttila [Finlande] | Progression and survival in Parkinson's disease |
| 002692 |
J. O. Rinne [Finlande] | Nigral degeneration in Parkinson's disease in relation to clinical features |
| 002693 |
U. K. Rinne [Finlande] | New strategies in the treatment of early Parkinson's disease |
| 002725 |
E. H. Heinonen [Finlande] ; R. Lammintausta [Finlande] | A review of the pharmacology of selegiline |
| 002823 |
Heinonen E. H [Finlande] ; Rinne U. K [Finlande] | Selegiline in the treatment of Parkinson's disease |
| 002826 |
Heinonen E. H [Finlande] ; Myllyl V ; Sotaniemi K ; Lammintausta R [Finlande] ; Salonen J. S [Finlande] ; Anttila M [Finlande] ; Savij Rvi M ; Kotila M ; Rinne U. K [Finlande] | Pharmacokinetics and metabolism of selegiline |
| 002836 |
R. J. Marttila [Finlande] ; U. K. Rinne [Finlande] | Epidemiological approaches to the etiology of Parkinson's disease |
| 002886 |
M. Hietanen [Finlande] ; Teräväinen [Finlande] | Dementia and treatment with L‐dopa in Parkinson's disease |
| 002919 |
A. Laihinen [Finlande] ; J. Alihanka [Finlande] ; S. Raitasuo [Finlande] ; U. K. Rinne [Finlande] | Sleep movements and associated autonomic nervous activities in patients with Parkinson's disease |
| 002980 |
M. Hietanen [Finlande] ; H. Ter V Inen [Finlande] | Cognitive performance in early Parkinson's disease |
| 002A04 |
S. Kaakkola [Finlande] ; P. T. M Nnistö [Finlande] ; E. Nissinen [Finlande] ; A. Vuorela [Finlande] ; R. M Ntyl [Finlande] | The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa |
| 002A80 |
U. K. Rinne [Finlande] | Problems associated with long‐term levodopa treatment of Parkinson's disease |
| 002A88 |
Patrick Goth Ni [Finlande] ; Markku Lehtinen [Finlande] ; Mika Fincke [Finlande] | Drugs for Parkinson's disease reduce tremor induced by physostigmine |
| 002A89 |
Reijo J. Marttila [Finlande] | Diagnosis and epidemiology of Parkinson's disease |
| 002B00 |
Reijo J. Marttila [Finlande] ; Urpo K. Rinne [Finlande] ; Anja Tiilikainen | Virus antibodies in Parkinson's disease |
| 002B26 |
Raimo Sulkava [Finlande] | Alzheimer's disease and senile dementia of Alzheimer type |
| 002B38 |
K. Rinne [Finlande] | Treatment of Parkinson's disease: Problems with a progressing disease |
| 002B50 |
J. Marttila [Finlande] ; K. Rinne [Finlande] | Epidemiology of Parkinson's disease—An overview |
| 002B51 |
K. Rinne [Finlande] ; P. Lönnberg [Finlande] ; V. Koskinen [Finlande] | Dopamine receptors in the parkinsonian brain |
| 002B91 |
Reijo J. Marttila [Finlande] ; Urpo K. Rinne [Finlande] | Changing epidemiology of Parkinson's disease: Predicted effects of levodopa treatment |
| 002C12 |
Rinne [Finlande] ; R. Marttila [Finlande] | Brain dopamine receptor stimulation and the relief of parkinsonism: Relationship between bromocriptine and levodopa |
| 002C27 |
J. Marttila [Finlande] ; K. Rinne [Finlande] ; T. Siirtola [Finlande] ; V. Sonninen [Finlande] | Mortality of patients with parkinson's disease treated with levodopa |
| 002C31 |
Reijo J. Marttila [Finlande] ; Urpo K. Rinne [Finlande] | DISABILITY AND PROGRESSION IN PARKINSON'S DISEASE |
| 002C47 |
Reijo J. Marttila [Finlande] ; Urpo K. Rinne [Finlande] | DEMENTIA IN PARKINSON'S DISEASE |
| 002C48 |
R. J. Marttila ; U. K. Rinne [Finlande] | Arteriosclerosis, heredity, and some previous infections in the etiology of parkinson's disease. A case-control study |
| 002C58 |
K. Rinne [Finlande] ; E. Birket-Smith [Danemark] ; E. Dupont [Danemark] ; E. Hansen [Danemark] ; M. Hyypp [Finlande] ; R. Marttila [Finlande] ; B. Mikkelsen [Danemark] ; H. Pakkenberg [Danemark] ; J. Presthus [Norvège] | Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (madopar®) in the treatment of Parkinson's disease |
| 002C94 |
K. Rinne [Finlande] ; V. Sonninen [Finlande] ; T. Siirtola [Finlande] | Treatment of Parkinson's disease with l -DOPA and decarboxylase inhibitor |
